Chiasma (NASDAQ:CHMA) Rating Lowered to Sell at ValuEngine

ValuEngine cut shares of Chiasma (NASDAQ:CHMA) from a hold rating to a sell rating in a research note issued to investors on Wednesday, ValuEngine reports.

Several other equities research analysts have also recently commented on the company. HC Wainwright reissued a buy rating and set a $11.00 target price on shares of Chiasma in a report on Tuesday, July 23rd. Cantor Fitzgerald set a $18.00 price target on shares of Chiasma and gave the stock a buy rating in a research report on Friday, September 13th. Brookline Capital Management restated a buy rating on shares of Chiasma in a research report on Wednesday, July 24th. Zacks Investment Research upgraded shares of Chiasma from a hold rating to a buy rating and set a $5.50 price target on the stock in a research report on Monday, September 30th. Finally, Piper Jaffray Companies assumed coverage on shares of Chiasma in a research report on Wednesday, July 31st. They issued an overweight rating and a $11.00 price target on the stock. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. Chiasma currently has a consensus rating of Buy and an average price target of $12.30.

NASDAQ:CHMA traded down $0.02 during midday trading on Wednesday, hitting $4.97. 134,741 shares of the stock were exchanged, compared to its average volume of 401,326. Chiasma has a one year low of $2.11 and a one year high of $9.25. The company has a market capitalization of $209.36 million, a price-to-earnings ratio of -3.88 and a beta of 1.18. The business has a 50-day moving average price of $5.18 and a two-hundred day moving average price of $6.07.

Chiasma (NASDAQ:CHMA) last announced its earnings results on Thursday, August 8th. The biotechnology company reported ($0.25) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.29) by $0.04. As a group, analysts forecast that Chiasma will post -1.09 earnings per share for the current fiscal year.

In other Chiasma news, Director Roni Mamluk sold 50,000 shares of Chiasma stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $5.59, for a total value of $279,500.00. Following the transaction, the director now owns 50,000 shares in the company, valued at $279,500. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Scott Minick acquired 9,818 shares of the stock in a transaction on Tuesday, August 20th. The shares were purchased at an average price of $5.19 per share, for a total transaction of $50,955.42. Following the completion of the transaction, the director now owns 62,531 shares in the company, valued at approximately $324,535.89. The disclosure for this purchase can be found here. Insiders own 8.30% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Quantitative Systematic Strategies LLC purchased a new position in Chiasma during the 2nd quarter worth approximately $100,000. Cubist Systematic Strategies LLC grew its position in Chiasma by 35.4% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 14,235 shares of the biotechnology company’s stock worth $106,000 after purchasing an additional 3,722 shares in the last quarter. Citadel Advisors LLC purchased a new position in Chiasma during the 2nd quarter worth approximately $145,000. Invesco Ltd. purchased a new position in Chiasma during the 2nd quarter worth approximately $186,000. Finally, Wells Fargo & Company MN purchased a new position in Chiasma during the 2nd quarter worth approximately $237,000. Hedge funds and other institutional investors own 52.97% of the company’s stock.

About Chiasma

Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.

Recommended Story: Equal Weight Rating

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Chiasma (NASDAQ:CHMA)

Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.